araag2/HINT huggingface dataset:
Clinical trial NCT01614691 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: sparc1203, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal
             allergic rhinitis and positive skin prick test

        Exclusion Criteria:

          -  History or presence of perennial allergic rhinitis

          -  Upper or lower respiratory tract infection 2 weeks before Visit 2

          -  Significant pulmonary disease other than allergic rhinitis or mild asthma controlled
             by beta-2-agonists alone

          -  Immunizations or vaccinations within 4 weeks prior to Visit 1
Clinical trial NCT00480987 (phase 1/phase 2, status: terminated)
Conditions: myelodysplastic syndromes, acute myeloid leukemia, leukemia
ICD codes: D46.9, D46.C, D46.Z, C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: oxaliplatin, fludarabine, cytarabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    lack of support.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed relapsed or refractory acute myeloid
             leukemia (AML) or high-risk myelodysplastic syndrome.

          -  Performance status 0-2 (Zubrod scale).

          -  Serum creatinine equal or less than 1.3 mg/dL or creatinine clearance > 40 mL/min.

          -  Bilirubin </= 2 mg/dL; serum glutamic oxaloacetic transaminase (SGOT) or Serum
             glutamic pyruvic transaminase (SGPT) </= 3 times the Upper Limit of Normal (ULN) for
             the reference lab unless due to leukemia or congenital hemolytic disorder (for
             bilirubin).

          -  Written informed consent.

        Exclusion Criteria:

          -  No untreated or uncontrolled life-threatening infection.

          -  No oxaliplatin, fludarabine, or cytarabine intolerance.

          -  No pregnancy or lactation. Female patients of childbearing potential (including those
             < 1 year post-menopausal) and male patients must agree to use contraception.

          -  No chemotherapy or radiation therapy within 4 weeks of study entry. Hydroxyurea is
             allowed prior to starting therapy in the setting of rapidly proliferating disease.

          -  No other medical condition, including mental illness or substance abuse, deemed by the
             Investigator to be likely to interfere with a patient's ability to sign informed
             consent or cooperate and participate in the study or to interfere with the
             interpretation of the results.
Clinical trial NCT01019473 (phase 2, status: terminated)
Conditions: huntington's disease, chorea
ICD codes: G10, G25.5, G25.4, I02.0, I02.9
Drugs: afq056, placebo
SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Huntington's disease (based on DNA testing polyQ >36) with a UHDRS maximal chorea
             score of >10

          -  patient with concomitant Huntington's medication (anti-depressants, neuroleptics,
             benzodiazepines) are allowed but the total daily dose and dosing regimen has to be
             stable for at least one months prior to randomization

          -  female patients without childbearing potential (post-menopausal or surgically
             sterilized), all patients must using a double-barrier local contraception

        Exclusion Criteria:

          -  patients with marked cognitive impairment (MMSE less than 18), with presence of
             psychosis and/or confusional states

          -  patients with a history or presence of renal impairment and/or liver disease Other
             protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00593853 (phase 2, status: terminated)
Conditions: prostatic neoplasms, fatigue
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1, R53.83, G93.3, R53.82, R53.0, T67.6XXS, T67.6XXA, T67.6XXD
Drugs: methylphenidate hydrochloride, matched placebo
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1, OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion:

          -  Age > 18 and ≤ 85 years

          -  Histologically confirmed prostate cancer

          -  Currently receiving LHRH-agonist therapy for greater than 6 months with measurable
             fatigue, defined as a score of >1 on the Bruera global fatigue severity scale OR

          -  Deemed eligible to commence LHRH-agonist therapy, with confirmation of fatigue at
             Screening Visit 2

          -  Have a serum PSA which is stable or decreasing based on the PSA trend over the last 2
             values taken at least 2 months apart, with the more recent value taken at least 2
             months after initiation of LHRH-agonist therapy.

          -  Have adequate liver and renal function (Bilirubin ≤ 1.5 x ULN and AST, ALT and Serum
             Creatinine < 2 x ULN)

          -  Able to swallow and retain oral medication

          -  Life expectancy of at least 1 year

          -  Able to read and write in English (and therefore accurately complete the required
             study questionnaires), understand instructions related to study procedures and give
             written informed consent.

        Exclusion:

          -  Current malignancy or received treatment for a previous malignancy within the last 3
             years other than prostate cancer (other exceptions are superficial bladder cancer or
             non-melanoma skin cancer)

          -  Previous chemotherapy within the last 5 years

          -  Anemia (Hemoglobin < 100 g/L)

          -  Myocardial infarction within past 6 months

          -  Any unstable serious co-existing medical condition(s) including but not limited to ;
             unstable or poorly controlled coronary artery disease, chronic atrial fibrillation,
             uncontrolled hypertension, uncontrolled diabetes, Severe bleeding diseases or immune
             disorders

          -  Severe depression as defined by CES-D score >27

          -  History of motor tics, seizures or a family history of Tourette's syndrome

          -  Infection with HIV (Human Immunodeficiency Virus), HBV (Hepatitis B) or HCV (Hepatitis
             C)

          -  Evidence of drug or alcohol abuse

          -  Known hypersensitivity to methylphenidate

          -  Possess any other contraindications to methylphenidate use
Clinical trial NCT00643448 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: azd1305, azd1305, placebo
SMILES: CC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2, CC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented Atrial Fibrillation but in stable SR for at least 2 h and a maximum of 28
             days.

          -  Sinus rhythm at randomisation

        Exclusion Criteria:

          -  Haemodynamically unstable condition as judged by the Investigator, systolic BP <100
             mmHg or >180 mmHg, or diastolic BP >105 mmHg at randomisation

          -  Personal or family history of Torsades de Pointes (TdP), any other polymorphic
             ventricular tachycardia (PVT), sustained ventricular tachycardia, long QT syndrome
             and/or Brugada syndrome

          -  Sinus bradycardia (<50 beats per minute (bpm)) at randomisation

          -  QTc (Fridericia, QTcF ) >450 ms measured in sinus rhythm at randomisation,

          -  Serum potassium below 3.8 or above 5.0 mmol/L or plasma potassium below 3.6 or above
             5.0 mmol/L

          -  QRS duration >120 ms at randomisation

          -  Use of any antiarrhythmic drug class I and/or III, digitalis glycoside, QT prolonging
             drug and/or drug that inhibits CYP3A4, as well as St John's Worth
Clinical trial NCT01641081 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: formoterol fumarate in the pressair dpi, low dose, formoterol fumarate in the pressair dpi, high dose, foradil aerolizer, low dose, foradil aerolizer, high dose, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusions:

          -  Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as
             defined in the GINA Guidelines) which is unlikely to exacerbate during the study
             (e.g., due to seasonal allergen exposure).

          -  Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at least 30
             days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use
             of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.

          -  Qualifying spirometry at Visit 1 demonstrates highest FEV1 is ≤ 85% and ≥ 60% of
             predicted for age, height, and gender using NHANES III (NHANES 2010) when
             bronchodilator medications have been withheld the appropriate length of time per the
             List of Concomitant Medications (Appendix III)

          -  Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after
             the administration of 360 µg of albuterol.

          -  Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the
             qualifying FEV1 at Visit 1

        Exclusions:

          -  Patients with any clinically significant respiratory conditions other than mild to
             moderate asthma, such as COPD, active tuberculosis, or history of interstitial lung
             disease

          -  Patients with a severe asthma exacerbation requiring hospitalization in the previous
             12 months

          -  Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at
             least 6 hours prior to visit
Clinical trial NCT01016366 (phase 2, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: lu aa24493, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has been diagnosed with FRDA and has had a genetic test demonstrating >400
             GAA nucleotide triplet repeats on the shorter of the two frataxin alleles

          -  The patient has a SARA (Stance) sub-score of <=6

          -  The patient has a SARA (Gait) sub-score of <=6

          -  Man or woman, aged 18 years or over

          -  If female then woman should agree not to try to become pregnant during the study, and
             use adequate protection/abstinence or not be of child bearing potential

        Exclusion Criteria:

          -  Clinically significant unstable illnesses such as liver, kidney, heart, stomach
             problems unrelated to their disease of FRDA

          -  Disallowed medications

          -  Serious underlying disease

          -  Clinically significant abnormal vital signs unrelated to the underlying disease of
             FRDA

          -  Abnormal laboratory blood results considered by the doctor as clinically significant,
             e.g.anaemia

          -  Treatment with idebenone within 6 weeks prior to screening

          -  Treatment with erythropoietin within 16 weeks prior to screening

          -  Clinically significant abnormal ECG

          -  Received or donated blood within previous 3 months

          -  Participation within another clinical trial within past 30 days

          -  Pregnancy or breast feeding

          -  History of drug allergies or hypersensitivities

          -  Current (or within past 6 months) disorder related to drug or alcohol abuse (as
             defined DSM-IV-TR)
Clinical trial NCT00398710 (phase 2, status: completed)
Conditions: waldenström's macroglobulinemia
ICD codes: C88.0
Drugs: perifosine
SMILES: CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Age >= 18 years.

          -  Must have received prior therapy for their WM and have relapsed or refractory WM. Any
             number of prior therapies is acceptable.

          -  Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a
             minimum IgM level of > 2 times the upper limit of each institution's normal value is
             required and over 10% of lymphoplasmacytic cells in the bone marrow.

          -  ECOG Performance Status (PS) 0, 1, or 2.

          -  The following laboratory values obtained 14 days prior to registration

          -  ANC >= 1 x109/L

          -  PLT >= 75 x109/L

          -  Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient
             is eligible.)

          -  AST <= 3 x upper limit of normal (ULN)

          -  Creatinine <= 2 x ULN

          -  Ability to provide informed consent.

          -  Life expectancy >= 12 weeks.

        Exclusion Criteria:

          -  Uncontrolled infection.

          -  Other active malignancies.

          -  CNS involvement.

          -  Cytotoxic chemotherapy ≤ 3 weeks, or biologic therapy ≤ 2 weeks, or corticosteroids ≤
             2 weeks, prior to registration. Patients may be receiving chronic corticosteroids if
             they are being given for disorders other than WM such as auto-immune diseases.
             Plasmapheresis is not considered as an active therapy and can be used at the
             physician's discretion.

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational.

          -  Any of the following:

          -  Pregnant women

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception (condoms, diaphragm, birth control pills, injections, intrauterine
             device (IUD), or abstinence, etc.)

          -  Known to be HIV positive.

          -  Radiation therapy ≤ 2 weeks prior to registration.
Clinical trial NCT01718938 (phase 2, status: completed)
Conditions: gastroparesis
ICD codes: K31.84
Drugs: velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo
SMILES: CC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=O, CC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=O, CC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper
             abdominal pain, retching or vomiting) for at least 3 months prior to Screening

          -  Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive

          -  Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score ≥2 and ≤4 at Screening

          -  Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) > 160
             minutes as determined by [13C]-octanoate breath test, at Screening

          -  Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging
             reasonably proximal to the diagnosis of gastroparesis

        Exclusion Criteria:

          -  Acute severe gastroenteritis within 2 weeks prior to Screening

          -  History of gastric outlet obstruction

          -  Prior history of gastric surgery, including but not limited to gastrectomy, gastric
             bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication

          -  Recurrent vomiting, defined as vomiting more than 2 days per week

          -  Hospitalization for treatment of gastroparesis or complications of diabetes within 4
             weeks prior to Screening

          -  Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal
             thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening

          -  If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >10% or a
             glucose > 250 mg/dL at Screening
Clinical trial NCT01235936 (phase 2, status: completed)
Conditions: anemia, kidney disease
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: akb-6548
SMILES: OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  18 to 79 years of age, inclusive

          -  Chronic Kidney Disease Stage 3 or Stage 4

          -  Hemoglobin (Hgb) < 10.5 g/dl

          -  TSAT > 20% and CBC indicating normocytic red blood cell morphology

        Key Exclusion Criteria:

          -  BMI > 40

          -  Red blood cell transfusion within 12 weeks.

          -  Androgen therapy within the previous 21 days prior to study dosing

          -  Therapy with any approved or experimental erythropoiesis stimulating agent (ESA)
             within the 10 weeks prior to the Screening visit

          -  Subjects meeting the criteria of ESA resistance within the previous 4 months

          -  Individual doses of intravenous iron of 250 mg or larger within the past 21 days

          -  AST or ALT >1.8x ULN.

          -  Alkaline phosphatase >2x ULN.

          -  Total bilirubin >1.5x ULN.

          -  Uncontrolled hypertension

          -  New York Heart Association Class III or IV congestive heart failure

          -  Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to
             dosing
Clinical trial NCT00134199 (phase 2/phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: cp-945,598, sibutramine
SMILES: CCNC1(CCN(CC1)C1=C2N=C(N(C2=NC=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl)C(N)=O, CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and/or female subjects without clinically relevant abnormalities identified by a
             detailed medical history, full physical examination, including blood pressure and
             pulse rate measurements, 12 lead ECG and clinical laboratory tests

          -  Body Mass Index (BMI) Â³30 and <40 kg/m2, for subjects with no additional

          -  co morbidities; BMI Â³27 kg/m2 and <40 kg/m2, for subjects with co morbidities
             [history of essential hypertension and/or dyslipidemia defined as high LDL (Â³160
             mg/dL) or high total cholesterol (Â³240 mg/dL)];

        Exclusion Criteria:

          -  Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or
             diastolic blood pressure of 90 mmHg or greater.

          -  Subjects with type 2 diabetes or fasting blood glucose concentration Â³126 mg/dL;

          -  Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa

          -  Subjects on prescription and non-prescription appetite or weight modifying drugs
Clinical trial NCT00269412 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: rifaximin
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female subject 18 years of age or older.

          2. Irritable bowel syndrome confirmed by the Rome II Criteria

          3. Lower endoscopic examination that demonstrates normal colonic anatomy

        Exclusion Criteria:

          1. Subject has exclusively constipation-predominant IBS (CIBS) that is characterized by <
             3 bowel movements/week or hard and lumpy stools.

          2. Subject has alternating IBS, but is currently presenting with constipation associated
             IBS symptoms.

          3. Subject has had adequate control of their DIBS and their symptom of bloating the week
             preceding the screening visit or at the time of randomization. Bloating includes the
             following symptoms: abdominal fullness, bloating, gas, or swelling.

          4. Subjects has a positive stool culture for O & P (ovum and parasite) and/or Clostridium
             difficile

          5. Subject has failed to record 2 negative weekly global assessments during the past 10
             days prior to randomization.
Clinical trial NCT00215657 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: degarelix, degarelix, degarelix, degarelix, degarelix, degarelix, degarelix, degarelix
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Reason stopped: 
    the doses were not effective in maintaining testosterone suppression
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males aged 18 or over

          -  Histologically proven adenocarcinoma of the prostate (all stages) in whom endocrine
             treatment was indicated (except neoadjuvant hormonal therapy)

          -  Has completed Study FE200486 CS07

          -  Has not met a withdrawal criteria at Visit 9 (day 28) in Study FE200486 CS07